07:00 , Sep 17, 2007 |  BC Week In Review  |  Company News

Marval Biosciences, University of Texas Health Science Center diagnostic news

The university spun out Marval to develop computed tomography (CT) contrast agents for cardiovascular imaging. The newco received an exclusive, worldwide license to the university's IP covering the preclinical agents, which are delivered using liposomal...
07:00 , Apr 2, 2007 |  BC Week In Review  |  Company News

Arrowhead, C Sixty deal

ARWR acquired nanotechnology company C Sixty for an undisclosed sum. C Sixty is developing fullerene antioxidants, which are water soluble, nanoscale forms of carbon. Arrowhead Research Corp. (ARWR), Pasadena, Calif.   C Sixty Inc. ,...
07:00 , Oct 20, 2003 |  BC Week In Review  |  Company News

C Sixty, Merck deal

Under an exclusive research and supply deal, MRK will seek to develop compounds in two undisclosed therapeutic areas based on C Sixty's fullerene antioxidants. MRK also obtained an option for a commercial license from C...
07:00 , May 20, 2002 |  BC Week In Review  |  Company News

C Sixty management update

C Sixty Inc. , Houston, Texas   Business: Chemistry   Hired: Robert Davis as CEO, formerly EVP at Sensus Drug Development Corp.  ...